DYNE THERAPEUTICS INC's ticker is DYN and the CUSIP is 26818M108. A total of 117 filers reported holding DYNE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $44,363,675 | -20.4% | 4,951,303 | 0.0% | 23.76% | -13.0% |
Q2 2023 | $55,702,159 | -2.3% | 4,951,303 | 0.0% | 27.32% | +14.9% |
Q1 2023 | $57,039,011 | -0.6% | 4,951,303 | 0.0% | 23.77% | -1.0% |
Q4 2022 | $57,385,602 | -8.7% | 4,951,303 | 0.0% | 24.01% | +0.3% |
Q3 2022 | $62,882,000 | +84.9% | 4,951,303 | 0.0% | 23.95% | +66.9% |
Q2 2022 | $34,015,000 | -28.7% | 4,951,303 | 0.0% | 14.35% | -12.0% |
Q1 2022 | $47,731,000 | -18.9% | 4,951,303 | 0.0% | 16.31% | +28.2% |
Q4 2021 | $58,871,000 | -26.8% | 4,951,303 | 0.0% | 12.72% | -31.7% |
Q3 2021 | $80,409,000 | -22.8% | 4,951,303 | 0.0% | 18.64% | -3.8% |
Q2 2021 | $104,175,000 | +35.5% | 4,951,303 | 0.0% | 19.37% | +30.4% |
Q1 2021 | $76,894,000 | -26.0% | 4,951,303 | 0.0% | 14.86% | +1.0% |
Q4 2020 | $103,977,000 | +4.0% | 4,951,303 | 0.0% | 14.71% | -21.1% |
Q3 2020 | $99,967,000 | – | 4,951,303 | – | 18.64% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vida Ventures Advisors, LLC | 2,960,046 | $35,195,000 | 13.16% |
MPM ASSET MANAGEMENT LLC | 4,951,303 | $58,871,000 | 12.72% |
Atlas Venture Life Science Advisors, LLC | 8,934,902 | $106,236,000 | 9.76% |
Logos Global Management LP | 3,234,392 | $38,457,000 | 3.97% |
GREAT POINT PARTNERS LLC | 845,000 | $10,047,000 | 2.23% |
Deep Track Capital, LP | 2,292,250 | $27,255,000 | 1.92% |
Octagon Capital Advisors LP | 583,649 | $6,940,000 | 1.35% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 476,000 | $5,641,000 | 1.26% |
COMMODORE CAPITAL LP | 305,125 | $3,628,000 | 0.84% |
RA Capital Management | 2,805,045 | $33,352,000 | 0.59% |